

Intraoperative Radiation Therapy for Carcinoma of the Pancreas

*Kazuyu Ebe**, *Eiichi Nishikawa**, *Hiroki Suda**, *Yutaka Honma**, *Mitsutoshi Kawamura**, *Morihisa Okada**, *Yuichi Karino**, *Taishi Nakada**, *Takashi Nakanishi**, *Tetsuzi Uchiyama***, *Yuichiro Hamanaka*** and *Takashi Suzuki***

Department of Radiology* and 2nd Department of Surgery**, Yamaguchi University School of Medicine, Ube 755, Japan

(Received September 4, revised October 24, 1991)

Abstract Intraoperative radiation therapy (IOR) was performed on 13 patients with carcinoma of the pancreas. Seven cases were resectable and 6 cases were unresectable. Tumor regression was observed in 5 of 6 unresectable tumors. Relief of abdominal pain was achieved in all 6 cases. The median survival of 13 patients was 145 days.

Intraarterial infusion of hypoxic cell radiosensitizer RK28 was examined as a model of future clinical application for IOR using a rabbit VX2 tumor system. The tumor regression slopes were statistically different ($P < 0.01$). But the difference in long-term survival was not statistically significant ($P < 0.10$). Intraarterial infusion of RK28 is clinically promising in the future.

Key Words : Intraoperative Radiation Therapy(IOR), Carcinoma, Pancreas, Intraarterial Infusion, Radiosensitizer, RK28, Rabbit, VX2 tumor

Introduction

Thirteen pancreatic carcinoma patients were treated with intraoperative radiation therapy(IOR) in our hospital during July 1988 to Feb.1990. This paper summarizes the finding of the experienced cases and also the effect of hypoxic cell radiosensitizer RK28 is shown in the future clinical application for IOR using rabbit VX2 tumor system.

Material and Methods

Thirteen patients with pancreatic adenocarcinomas, 9 men and 4 women ranging in age from 36 to 75 years, were treated with IOR during July '88 to Feb.'90. Clinical staging followed the General Rules for Cancer of the Pancreas(Japan Pancreas Society, 1986)(Table 1). Four patients

were in stage III, 9 patients in stage IV. There were 7 resectable and 6 unresectable tumors. Five patients had liver metastases and 5 had peritoneal metastases. The IOR was delivered to the tumor or the tumor bed. Electron beams of 12 MeV and 15 MeV at doses of 25 Gy were single-irradiated using cone-shaped applicators of 6cm, 8cm and 10cm in diameter. Additional external radiation therapy (ERT) was given to 8 patients with 10 MV of X-rays in 200cGy fractions up to 60 Gy. Hyperthermia therapy was added to 7 patients using 13.5 MHz of RF with 400 watts for 40 min at once (Table 2). A survival curve was determined using Kaplan-Meier method.

In animal experiments, rabbit VX2 tumor was maintained by serial transplantation. Solid tumors of 3cm in diameter ($n=6$) were irradiated with 15 Gy of X-rays (200 kVp, 10 mA, 70 cGy/min) a minute after intraarterial infusions of

Table 1 Patients characteristics

Case	C.C.		Stage
1.	42yo	F jaudice	III (Ph·T ₃ ·N(-)·S ₀ ·Rp ₀ ·PV ₀ ·CH ₃ ·A ₀ ·Plx(-)·H ₀)
2.	59yo	M (melena)	III (Pb·T ₂ ·N ₁ (+)·S ₂ ·Rp ₁ ·PV ₁ ·CH ₀ ·H ₀)
3.	60yo	M jaudice	III (Ph·T ₃ ·N(+).S ₂ ·Rp ₂ ·PV ₀ ·CH ₃ ·Plx(-)·H ₀)
4.	75yo	F jaudice	III (Phb·T ₂ N ₁ (+)·S ₀ ·Rp ₂ ·PV ₂ ·CH ₃ ·Plx(-)H ₀)
5.	56yo	M jaudice	IV (Ph·T ₃ ·N ₃ (+)·S ₂ ·Rp ₁ ·PV ₁ ·CH ₃ ·A ₃ ·Plx(-)·H ₀)
6.	72yo	M jaudice	IV (Phb·T ₂ ·N ₃ (+)·S ₂ ·Rp ₂ ·PV ₂ ·CH ₃ ·A ₁ ·Plx(-)·H ₀)
7.	46yo	M back pain	IV (Ph-b·T ₃ ·S ₃ ·Rp ₃ ·PV ₃ ·A ₃ ·Plx(-)·P ₂ ·H ₂)
8.	55yo	M epigastralgia	IV (Ph-b·T ₄ ·N ₁ (+)·S ₃ ·Rp ₃ ·PV ₃ ·CH ₃ ·A ₃ ·H ₁)
9.	53yo	M epigastralgia	IV (Phbt·T ₄ ·N ₃ (+)·S ₃ ·Rp ₃ ·PV ₃ ·A ₃ ·P ₃ ·H ₀)
10.	68yo	F epigastralgia	IV (Pb·T ₂ ·N ₃ (+)·S ₁ ·Rp ₁ ·PV ₁ ·A ₀ ·P ₀ ·H ₀)
11.	36yo	M epigastralgia	IV (Ph·T ₃ ·N ₂ (-)·S ₃ ·Rp ₃ ·PV ₃ ·CH ₃ ·A ₂ ·Plx(-)·P ₂ ·H ₁)
12.	56yo	F epigastralgia	IV (Pb·T ₄ ·N ₃ (+)·S ₃ ·Rp ₂ ·PV ₃ ·A ₃ ·P ₂ ·H ₃)
13.	67yo	M jaundice	IV (Ph·T ₃ ·N ₂ (+)·S ₃ ·Rp ₃ ·PV ₃ ·CH ₂ ·Plx(+).P ₁ ·H ₁)

Table 2 Treatment characteristics

Case	Surgery	IOR	External Radi.therapy	Hyper-thermia	pain relief	outcome
1.	abs.cur.	25 Gy, φ8cm 10MeV Elec.	30 Gy, 9×7cm 10 MV X-ray	10 times		20 month alive
2.	abs.cur.	25 Gy, φ8cm 12MeV Elec.	none	none		0.5 month dead
3.	abs.cur.	25 Gy, φ6cm 12MeV Elec.	none	none		13.5 month dead
4.	abs.cur.	25 Gy, φ8cm 12MeV Elec.	40 Gy, 7×6cm 10 MV X-ray	10 times		13 months alive
5.	rel. non-cur.	25 Gy, φ8cm 12 MeV Elec.	4 Gy, 6×8cm 10 MV X-ray	none		3 month dead
6.	rel. non-cur.	25 Gy, φ8cm 12 MeV Elec.	none	none		3.5 month dead
7.	unresec.	25 Gy, φ10cm 15 MeV Elec.	none	none	+	4 month dead
8.	unresec.	25 Gy, φ8cm 15 MeV Elec.	58 Gy, 6×7cm 10 MV X-ray	10 times	+	2.5 month dead
9.	unresec.	25 Gy, φ6cm 12 MeV Elec.	50 Gy, 6×7cm 10 MV X-ray	9 times	+	5 month dead
10.	abs. non-cur.	25 Gy, φ8cm 12 MeV Elec.	none	none	+	8.5 month alive
11.	unresec.	25 Gy, φ8cm 12 MeV Elec.	40 Gy, 14×10cm 10 MV X-ray	5 times	+	6.5 month dead
12.	unresec.	25 Gy, φ8cm 12 MeV Elec.	(pre) 30 Gy (post) 30 Gy	3 times	+	5 month dead
13.	unresec.	25 Gy, φ8cm 12 MeV Elec.	(pre) 60 Gy 10 MV X-ray	10 times		0.5 month dead

RK28^{1),2)} (80mg/kg b.w., 50mg/ml in saline) via the saphenous artery³⁾. The CT scans were performed to evaluate a tumor volume with 8-mm thickness at 10-mm intervals. Statistical comparisons were made with tests for tumor regression slopes. Survival curves were determined using Kaplan-Meier method, then statistical comparisons were made using the generalized Wilcoxon

test.

Results

Tumor regression of pancreatic cancer was observed 5 of 6 unresectable tumors except case 13. Relief of pain was achieved in all 6 patients. The median survival was obtained

of 145 days (Fig.1). Five patients (cases 5, 7, 9, 11 and 12) died due to hepatic metastases and/or peritoneal metastases, 3 patients (case

3, 8 and 13) due to gastro-intestinal bleedings, a patient(case 2) due to pancreatic fistula and a patient (case 6) due to sepsis. Three patients are alive. Case 9 was shown in Fig. 2. The tumor almost disappeared 4 months after IOR. The effect of intraarterial infusion of RK28 was shown in Fig.3. The tumor regression slopes were statistically different($p < 0.01$). The radiosensitizing effect was observed. But survival curves were not statistically different ($p < 0.10$) (Fig. 4).




Fig.1 Survival curve of 13 patients




Fig.2 Case 9.
a) before treatment
b) Four months after treatment

Discussion

It is well known that IOR improves local tumor control though it does not contribute survival rates^{4,5}. In this study, we cannot show if IOR works well or not because ERT alone, which means control, was not done.




Fig.3 Tumor regression curves in rabbit VX2 tumor system.
group A;control n=6 (○), B;15 Gy alone n=6 (△), C;15 Gy+RK28 i.a. n=6 (□).
B vs C($p < 0.01$).




Fig. 4 Survival curves in rabbit VX2 tumor system. group A; control n=6 (○), B; 15 Gy alone n=6 (△), C; 15 Gy+RK28 i.a. n=6 (□). B vs C ($p < 0.10$).

However, it is clear that irradiation including both IOR and ERT is effective since tumor regression was observed in 5 out of 6 unresectable tumors except case 13 who died within a half month. It is believed that IOR destroys only tumor tissue and minimizes damages of normal tissues. If additional ERT is delivered, tumor cell killing by irradiation will be increased. Our results shows that survival benefits seems to be low. One of the reasons may be hematogenous and/or peritoneal spread of tumor cells rather than local failures. Effective treatments for distant metastases are strongly expected.

In animal experiments, the radiosensitizing effect of RK28 was found by means of its intraarterial infusion which provides twice concentration in tumor tissue as much as intravenous infusion (data not shown). Intraarterial infusion of RK28 is clinically promising in the future, though misonidazole was not effective⁹⁾.

References

- 1) Sakaguchi, M., Larroquette, C.A. and Agrawal, K.C. : Potential radiosensitizing agents. 6.2-nitroimidazole nucleosides: Arabinofuranosyl and hexopyranosyl analogues. *J. Med. Chem.*, **26** : 20-24, 1983.
- 2) Murayama, C., Tanaka, N., Miyamoto, Y., Sakaguchi, M. and Mori, T. : In vitro and in vivo radiosensitizing effects of 2-nitroimidazole derivatives with sugar component. *Strahlentherapie und Onkologie*, **163** : 385-390, 1987.
- 3) Honma, Y., Suda, H., Ebe, K., Hatanaka, M. and Nakanishi, T. : Simplified intraarterial infusion and angiographic method for rabbit VX2 hind limb tumor via saphenous artery. *Nippon Act. Radiol.*, **50** : 426-428, 1990.
- 4) Gunderson, L.L., Martin, J.K., Nagorney, D. M., Fieck, J.M., Wieand, H.S., Martnez, A., O'Connell, M.J., Earle, J.D. and McClrath, D. C. : Intraoperative and external beam +/- 5-FU for locally advanced pancreatic cancer. *Int. J. Radiat. Oncol. Biol. Phys.*, **13** : 319-329, 1987.
- 5) Roldan, G.E. Gunderson, L.L., Nagorney, D. M., Martin, J.K., Ilstrup, D.M., Holbrook, M. A., Kvols, and McClrath, D.C. : External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. *Cancer*, **61** : 1110-1116, 1988.
- 6) Tepper, J.E., Shipley, W.U., Warshaw, A.L.,

Nardi, G.L., Wood, W.C. and Orlow, E.L. :
The role of misonidazole combined with
intraoperative radiation therapy in the treat-
ment of pancreatic carcinoma. *J. Clin.
Oncol.*, **5** : 579-584, 1987.